Vascular endothelial growth factor

PanOptica to Present Positive Topical Anti-VEGF Eye Drop Data at OIS@AAO

Retrieved on: 
Monday, October 7, 2019

PAN-90806 is a once-daily topical formulation of a small-molecule anti-vascular endothelial growth factor (anti-VEGF) eye drop for the treatment of neovascular eye diseases, including neovascular age-related macular degeneration (wet AMD).

Key Points: 
  • PAN-90806 is a once-daily topical formulation of a small-molecule anti-vascular endothelial growth factor (anti-VEGF) eye drop for the treatment of neovascular eye diseases, including neovascular age-related macular degeneration (wet AMD).
  • In pre-clinical research using validated ocular angiogenesis models, topically administered PAN-90806 in the form of an eye drop suppressed the formation of new blood vessels.
  • In non-clinical pharmacokinetic studies, topical administration of PAN-90806 achieved significant and sustained levels in the retina and choroid of multiple species, supporting further investigation of PAN-90806.
  • The company seeks early-stage assets translated from other diseases and develops select candidates through human clinical proof of concept.

Kodiak Sciences Announces Upcoming Presentation of Durability Data from Clinical Development Program of KSI-301 in Wet AMD, DME, and RVO at American Academy of Ophthalmology 2019 Annual Meeting

Retrieved on: 
Monday, October 7, 2019

"We were very pleased with the early durability data from patients with wet AMD treated with KSI-301 in our Phase 1b clinical study announced last month at The Retina Society Annual Meeting.

Key Points: 
  • "We were very pleased with the early durability data from patients with wet AMD treated with KSI-301 in our Phase 1b clinical study announced last month at The Retina Society Annual Meeting.
  • Those data underscored our belief in the potential for KSI-301 to be a leading, next-generation anti-VEGF with a long-interval durability profile," said Victor Perlroth, M.D., Chief Executive Officer of Kodiak Sciences.
  • We look forward to further engaging with the community about the new data and our planning for the clinical development of KSI-301."
  • "Kodiak," "ABC Platform" and the Kodiak logo are registered trademarks or trademarks of Kodiak Sciences Inc. in various jurisdictions.

Chi-Med Highlights Oral Presentations at 2019 CSCO Annual Meeting

Retrieved on: 
Wednesday, September 18, 2019

Results of the FRESCO study were initially presented in an oral presentation at the American Society of Clinical Oncology Annual Meeting on June 5, 2017 and published in The Journal of the American Medical Association, JAMA, in June 2018 (clinicaltrials.gov identifier: NCT02314819 ).

Key Points: 
  • Results of the FRESCO study were initially presented in an oral presentation at the American Society of Clinical Oncology Annual Meeting on June 5, 2017 and published in The Journal of the American Medical Association, JAMA, in June 2018 (clinicaltrials.gov identifier: NCT02314819 ).
  • Fruquintinib is a highly selective and potent oral inhibitor of vascular endothelial growth factor receptor (VEGFR) 1/2/3.
  • VEGFR inhibitors play a pivotal role in blocking tumor-related angiogenesis, cutting off the blood supply that a tumor needs to grow rapidly.
  • Earlier results of this study were first presented on March 31, 2019 at the American Association of Cancer Research (AACR) Annual Meeting 2019 (clinicaltrials.gov identifier: NCT02897479 ).

Kodiak Sciences Announces Upcoming Presentations at EURETINA Meeting

Retrieved on: 
Wednesday, September 4, 2019

"At EURETINA, we will report on outcomes with over 100 patients dosed and a growing safety database with over 250 injections of KSI-301.

Key Points: 
  • "At EURETINA, we will report on outcomes with over 100 patients dosed and a growing safety database with over 250 injections of KSI-301.
  • The data being presented continue to demonstrate the potential for KSI-301 to be a first-line intravitreal anti-VEGF therapy."
  • Kodiak is a clinical-stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases.
  • "Kodiak," "ABC Platform" and the Kodiak logo are registered trademarks or trademarks of Kodiak Sciences Inc. in various jurisdictions.

Adverum Biotechnologies to Present 24-Week Data from First Cohort of OPTIC Trial of ADVM-022 Intravitreal Injection Gene Therapy to Treat Wet AMD at the American Academy of Ophthalmology 2019 Annual Meeting in October

Retrieved on: 
Wednesday, August 28, 2019

Wet AMD is an aggressive disease that often requires frequent anti-VEGF injections over the long-term in order to reduce vision loss, said Aaron Osborne, MBBS, MRCOphth, chief medical officer of Adverum Biotechnologies.

Key Points: 
  • Wet AMD is an aggressive disease that often requires frequent anti-VEGF injections over the long-term in order to reduce vision loss, said Aaron Osborne, MBBS, MRCOphth, chief medical officer of Adverum Biotechnologies.
  • We look forward to presenting 24-week data from the first cohort of patients in the OPTIC trial at the upcoming AAO meeting.
  • Adverum is a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases.
  • Adverum develops gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein.

Aerie Pharmaceuticals Initiates First-in-Human Clinical Trial of AR-13503 Sustained Release Intravitreal Implant in Patients with Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema

Retrieved on: 
Tuesday, August 20, 2019

Aflibercept is a vascular endothelial growth factor (VEGF) inhibitor approved for the treatment of retinal diseases.

Key Points: 
  • Aflibercept is a vascular endothelial growth factor (VEGF) inhibitor approved for the treatment of retinal diseases.
  • The AR-13503 SR Implant is a bio-erodible polyesteramide polymer implant that provides controlled release of AR-13503, a proprietary, small-molecule inhibitor of both Rho kinase and Protein kinase C, over a sustained period.
  • Aerie continues to focus on global expansion and the development of additional product candidates and technologies in ophthalmology, including for wet age-related macular degeneration and diabetic macular edema.
  • Any forward-looking statements that we make in this press release speak only as of the date of this press release.

FDA Approves EYLEA® (aflibercept) Injection Prefilled Syringe

Retrieved on: 
Tuesday, August 13, 2019

(NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the Chemistry, Manufacturing and Controls (CMC) Prior-Approval Supplement (PAS) for the EYLEA(aflibercept) Injection prefilled syringe.

Key Points: 
  • (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the Chemistry, Manufacturing and Controls (CMC) Prior-Approval Supplement (PAS) for the EYLEA(aflibercept) Injection prefilled syringe.
  • Market supply of the EYLEA prefilled syringe is expected to be available to physicians and patients this year.
  • The sterilized prefilled syringe offers the same medicine as the currently available EYLEA, in an easier to use and administer presentation.
  • EYLEA (aflibercept) Injection is a vascular endothelial growth factor (VEGF) inhibitor formulated as an injection for the eye.

Opthea to Host Investor Teleconference

Retrieved on: 
Monday, August 5, 2019

Opthea is developing OPT-302 for use in combination with inhibitors of VEGF-A (eg.

Key Points: 
  • Opthea is developing OPT-302 for use in combination with inhibitors of VEGF-A (eg.
  • Companies such as Opthea are dependent on the success of their research and development projects and on the ability to attract funding to support these activities.
  • Opthea strongly recommends that professional investment advice be sought prior to such investments.
  • Opthea undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Size Worth $10.2 Billion by 2023 - Technavio

Retrieved on: 
Monday, July 8, 2019

The global vascular endothelial growth factor inhibitors market size is poised to reach USD 10.2 billion by 2023, according to a new report by Technavio, progressing at a CAGR of more than 8% during the forecast period.

Key Points: 
  • The global vascular endothelial growth factor inhibitors market size is poised to reach USD 10.2 billion by 2023, according to a new report by Technavio, progressing at a CAGR of more than 8% during the forecast period.
  • View the full release here: https://www.businesswire.com/news/home/20190708005077/en/
    Technavio has published a new market research report on the global vascular endothelial growth factor (VEGF) market from 2019-2023.
  • The North-American vascular endothelial growth factor inhibitors market accounted for more than 47% of the overall revenue in 2018, owing to the sales of approved VEGF inhibitors and the increasing prevalence of several cancer indications, including RCC, melanomas, and NSCLC.
  • Technavio has segmented the global vascular endothelial growth factor inhibitors market based on the application (oncology and ophthalmology) and region (North America, Europe, Asia, and ROW).

Fotivda (tivozanib; AVEO Oncology/EUSA Pharma/Kyowa Hakko Kirin) Overview 2019: An Oral Tyrosine Kinase Inhibitor Targeting Vascular Endothelial Growth Factor Receptor 1 (VEGFR-1), VEGFR-2, & VEGFR-3

Retrieved on: 
Wednesday, June 26, 2019

DUBLIN, June 26, 2019 /PRNewswire/ -- The "Fotivda" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, June 26, 2019 /PRNewswire/ -- The "Fotivda" report has been added to ResearchAndMarkets.com's offering.
  • Fotivda (tivozanib; AVEO Oncology/EUSA Pharma/Kyowa Hakko Kirin) is an oral tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor 1 (VEGFR-1), VEGFR-2, and VEGFR-3.
  • Inhibition of VEGF signaling in order to prevent angiogenesis is a well-established strategy across many tumor types; however, Fotivda's potency, selectivity, and long half-life are hypothesized to improve the drug's efficacy and safety in comparison to its predecessors.
  • In the US, the initial New Drug Application, also based on the TIVO-1 clinical trial data, was met with a complete response letter from the US Food and Drug Administration (FDA).